Original Article

Novel *N*-2-(Furyl)-2-(Chlorobenzyloxyimino) Ethyl Piperazinyl Quinolones: Synthesis, Cytotoxic Evaluation and Structure-Activity Relationship

Negar Mohammadhosseini[a], Mahboobeh Pordeli[b], Maliheh Safavi[c], Loghman Firoozpour[d],
Fatemeh Amin[e], Sussan Kabudanian Ardestani[b], Najmeh Edraki[f], Abbas Shafiee[g] and Alireza Foroumadi[d,g]*

[a]Young Researchers and Elite Club, Islamshahr Branch, Islamic Azad University, Tehran, Iran. [b]Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. [c]Biotechnology Department, Iranian Research Organization for Science and Technology (IROST), Tehran, Iran. [d]Drug Design and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran. [e]School of Chemistry, University College of Science, University of Tehran, Tehran, Iran. [f]Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. [g]Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Quinolone antibacterials are one of the most important classes of pharmacological agents known as potent inhibitors of bacterial DNA gyrase and topoisomerase IV that efficiently inhibit DNA replication and transcription by generating several double-stranded DNA break. Some quinolone derivatives demonstrated inhibitory potential against eukaryote topoismarase II and substantial dose-dependent cytotoxic potential against some cancerous cells. In present study, synthesis and cytotoxic activity evaluation of new series of *N*-pipearzinyl quinolones containing *N*-2-(furyl-2 or 3-yl)-2-(chlorobenzyloxyimino) ethyl moiety 7a-i have been studied. Reaction of quinolone, with 2-bromo-1-(furan-2 or 3-yl)ethanone-*O*-substituted chlorobenzyloxime in DMF in presence of NaHCO$_3$ at room temperature, gave the title compounds *N*-2-(furan-2 or 3-yl)-2-(chlorobenzyloxyiminoethyl) quinolone 7a-i. Synthesized compounds were further evaluated *in-vitro* against three human breast tumor cell lines. Preliminary screening indicated that compound 7 g demonstrated significant growth inhibitory potential against all evaluated cell lines. The results of structure-activity relationship study exhibited that quinolone derivatives are superior in cytotoxic potential compared to 1,8-naphthyridone series. Furthermore, ethyl quinolone derivatives were more potent cytotoxic agents comparing with cyclopropyl quinolones.

Keywords: Furyl; *N*-pipearzinyl quinolones; Cytotoxic activity.

Introduction

Quinolones are bicyclic ring structures containing 4-oxo-1,4-dihydroquinoline core and different substituted moieties at N-1 position and demonstrate a wide range of pharmacological effects (1-3). Some important quinolone derivatives (*e.g.* ciprfloxacin) containing various substitutes at different positions of quinolone central core, have been primarily known as potent antibacterial agents that target type II bacterial topoisomerases (DNA gyrase and topoisomerase IV) and efficiently

inhibit DNA replication and transcription by generating several double-stranded DNA break (4-6). Several researches have indicated that some quinolone derivatives display inhibitory potential against eukaryote topoismarase II. Therefore, in addition to antibacterial activity, some member of quinolones demonstrated substantial dose-dependent growth inhibitory potential against some cancerous cells (7-10). Moreover, a variety of cytotoxic mechanism such as apoptotic induction and inhibition of tubulin polymerization have been postulated as a plausible mechanism responsible for anticancer activity of cytotoxic quinolones (11-13).

According to above findings and based on ciprofloxacin and norfloxacin core (Figure 1), several novel quinolone derivatives were synthesized and displayed significant anticancer activity. Structure-activity relationship study of cytotoxic quinolones demonstrated that substitution of aromatic moieties at C-7 position of quinolone central nucleus mainly affect the anticancer activity of these compounds and enhances selectivity toward type II of human topoisomerase rather than bacterial type (9, 14, 15). Chemical structure of some potent cytotoxic quinolones containing aromatic and heteroaromatic substitutes at C-7 position such as 7-pyridinyl (WIN57294) and 7-hydroxyphenyl (CP-115, 953) are demonstrated in Figure 1 (9). Moreover, 7-pyperzinyl derivatives of tricyclic quinolones such as isothiazoloquinolones A-65281 (Figure 1) induces significant DNA-breakage mediated by Calf thymus topoisomerase II and demonstrated cytotoxic potential nearly as potent as etoposide (16). We have previously reported cytotoxic activity of *N*-substituted pipearzinyl quinolone derivatives of ciprofloxacin type containing *N*-2-(furyl-2-yl)-2 (chlorobenzyloxyimino) ethyl moiety, *N*-[2-(5-chlorothiophen-2-yl)-2-oxoethyl] or *N*-[2-(5-chlorothiophen-2-yl)-2-oxyiminoethyl]piperazinyl moiety against some human tumor cell lines (17, 18). The results indicate that introduction of aforementioned substitutes into piperazine ring of quinolone derivatives resulted in enhanced cytotoxic potential in some cases. In continuation of our ongoing research program on finding the potent anticancer scaffolds (19-23) and in attempt to construct structure-activity relationship of these type of cytotoxic quinolones, in the current study, we report the synthesis and cytotoxic activity of novel derivatives of 6-fluoro-quinolone 3-carboxylic acid and 6-fluoro-1,8-naphthyridone 3-carboxylic acid core containing *N*-2-(2-furyl)-2-(chlorobenzyloxyimino) ethyl or *N*-2-(3-furyl)-2-(chlorobenzyloxyimino) ethyl piperazinyl pendant.

Experimental

Chemistry

A Kofler hot stage apparatus was used for the measurement of reported melting. The IR spectra were recorded on a Nicollet FT-IR Magna 550 spectrometer. The ^{1}HNMR spectra were recorded on Bruker FT-500 MHz spectrometer and chemical shifts (δ) are reported in ppm relative to internal tetramethylsilane. Mass spectra were recorded on an Agilent Technology (HP) mass spectrometer operating at an ionisation potential of 70 eV. Analytical thin layer chromatography (TLC) on Merck silicagel 60 F254 plates using various mobile phases of different polarities was performed in order to confirm the purity of final products.

General method for the synthesis of O-benzyloximes derivatives 5a-f

To a mixture of hydroxylamine hydrochloride (0.4 mol), Sodium carbonate anyhydrous (0.6 mol) in 185 mL H_2O was dropped ethyl chloro formate (0.23 mol). After completion of the reaction, precipitate was extracted with diethyl ether to give *N*-hydroxyurethane 1. Stirring a mixture of compound 1(0.68 mol) and chlorobenzylchloride derivatives (0.42 mol) in 120 mL EtOH gave chlorobenzyl carbethoxy hydroxamate derivatives 2a-c. Compound 2a-c (40 mmol) and sodium hydroxide (80 mmol) in 50 mL EtOH was refluxed for 2 hours. The precipitated product 3a-c was filtered off, dried, and recrystallized from ethanol and water. Compounds 5a-f were prepared from 2-bromo-(furan -2 or 3- yl)-ethanone 4a-b (1 mmol) and substituted *O*-benzylhydroxylamine hydrochlorides 3a-c (2 mmol) in methanol (10 mL) at room temperature for 3 days (Scheme 1) (19).

Figure 1. Chemical structure of antibacterial (Ciprofloxacin and Norfloxacin) and some anticancer quinolones (CP115,953, WIN57294 and A-65281).

General method for the synthesis of N-2-(2 or 3-furyl)-2-(chlorobenzyloxyimino) ethyl quinolone (7a-i)

A mixture of 2-bromo-1-(furan-2 or 3-yl) ethanone *O*-2-chlorobenzyl oxime derivatives 5a-f (0.55 mmol), quinolone derivatives 6a-c (0.5 mmol) and NaHCO$_3$ (0.5 mmol) in DMF (5 mL) was stirred at room temperature for 6-9 days. After completion, water (20 mL) was added and the precipitate was filtered off, washed with water and recrystallized from EtOH-CHCl$_3$ to give target compounds 7a-i.

7-(4-(2-(benzyloxyimino)-2-(furan-3-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid 7a (18)

Yield 54%; m.p. 217 - 218 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.40 (t, 3H, *J*=7 Hz, CH$_3$), 3.23 -3.32 (m, 4H, piperazine), 3.58-3.65 (m, 4H, piperazine), 3.62 (s, 2H, CH$_2$), 4.58 (q, 2H, *J*=7 Hz, CH$_2$-CH$_3$), 5.20 (s, 2H, OCH$_2$), 6.71 (s, 1H, furyl), 7.17 (d, 1H, *J*=7.1Hz, H$_8$), 7.29-7.43 (m, 5H, phenyl), 7.70 (s, 1H, furyl), 7.93 (d, 1H, *J*=13.2Hz, H$_5$), 8.25 (s, 1H, furyl), 8.95 (s, 1H, H$_2$), 15.34 ppm (s, 1H, COOH). IR (KBr): 1681,

1619 (C=O). MS *m/z* 532 (M$^+$, 5), 425 (12), 332 (100), 139 (26).

7-(4-(2-(4-chlorobenzyloxyimino)-2-(furan-2-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid 7b

Yield 85%; m.p. 248–250 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.40 (t, *J*=7 Hz, 3H, CH$_3$), 2.62-2.70 (m, 4H, piperazine), 3.23-3.30 (m, 4H, piperazine), 3.64 (s, 2H, CH$_2$), 4.57 (q, *J*=7.0 Hz, 2H, CH$_2$), 5.20 (s, 2H, OCH$_2$), 6.56-6.70 (m, *J*=3.3 Hz, 1H, furyl), 7.15 (d, *J*=7.15 Hz, 1H, H$_8$), 7.43-7.49 (m, 4H, benzyl), 7.74 (s,1H, furyl), 7.92 (d, *J*=13.2 Hz, 1H, H$_5$), 8.95 (s,1H, H$_2$), 15.14 ppm (s, 1H, COOH); IR (KBr): 1731, 1629 (C=O). MS *m/z* 566 (M$^+$, 3), 332 (40), 316 (21), 233 (25), 125 (100).

7-(4-(2-(2-chlorobenzyloxyimino)-2-(furan-2-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid 7c

Yield 73%; m.p. 277–278 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.40 (t, *J*=6.8 Hz, 3H, CH$_3$), 2.45-2.76 (m, 4H, piperazine), 3.25-3.53 (m, 4H, piperazine), 3.61 (s, 2H, CH$_2$), 4.56 (q, *J*=6.8Hz, 2H, CH$_2$), 5.27 (s, 2H, OCH$_2$), 6.50 (d, *J*=3.2 Hz, 1H, furyl), 6.98 (d, *J*=3.2 Hz, 1H, furyl), 7.14 (d, *J*=6.8 Hz, 1H, H$_8$), 7.30-7.40 (m, 4H, benzyl), 7.55 (t, *J*=3.2 Hz, 1H, furyl), 7.89 (d, *J*=13.2 Hz, 1H, H$_5$), 15.29 ppm (s, 1H, COOH); IR (KBr): 1741, 1629 (C=O). MS *m/z* 566 (M$^+$, 2), 318 (19), 234 (24), 141 (100).

7-(4-(2-(2-chlorobenzyloxyimino)-2-(furan-2-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid 7d

Yield 57%; m.p. 265–267 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.38 (t, *J*=6.8Hz, 3H, CH$_3$), 2.80-2.91 (m, 4H, piperazine), 3.62 (s, 2H, CH$_2$), 3.73-3.86 (m, 4H, piperazine), 4.46 (q, *J*=6.8 Hz, 2H, CH$_2$), 5.26 (s, 2H, OCH$_2$), 6.58(d, *J*=3.2 Hz, 1H, furyl), 6.99 (d, *J*= 3.2Hz, 1H, furyl), 7.28-7.59 (m, 4H, benzyl), 8.02 (d, *J*=13.6 Hz, 1H, H$_5$), 8.06 (bs, 1H, furyl), 8.92 (s, 1H, H$_2$), 15.15 ppm (s, 1H, COOH); IR (KBr): 1629 (C=O). MS *m/z* 566 (M$^+$, 2), 319 (18), 234 (21), 141 (100).

7-(4-(2-(4-chlorobenzyloxyimino)-2-(furan-3-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid 7e

Yield: 48%; m.p. 270–272 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.41(t, *J*=7.0 Hz, 3H, CH$_3$), 2.56-2.64 (m, 4H, piperazine), 3.20-3.28 (m, 4H, piperazine), 3.61(q, *J*=7.0 Hz, 2H, CH$_2$), 5.15 (s, 2H, OCH$_2$), 6.69 (d, *J*=2.7 Hz, 1H, furyl), 6.95 (d, *J*=2.7 Hz, 1H, furyl), 7.15 (d, *J*=7.1 Hz, 1H, H$_8$), 7.42-7.46 (m, 4H, benzyl), 7.73 (bs, 1H, furyl), 7.90 (d, *J*=13.2 Hz, 1H, H$_5$), 8.93 (s, 1H, H$_2$), 15.12 ppm (s, 1H, COOH); IR (KBr): 1728, 1631 (C=O). MS *m/z* 566 (M$^+$, 2), 318 (31), 234 (17), 141 (100).

7-(4-(2-(4-chlorobenzyloxyimino)-2-(furan-3-yl) ethyl) piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 7f

Yield: 66%; m.p. 230-231 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.36 (t, *J*=6.7 Hz, 3H, CH$_3$), 2.53-2.59 (m,4H, piperazine), 3.57 (s, 2H, CH$_2$), 3.70-3.80 (m, 4H, piperazine), 4.46 (q, *J*=6.7 Hz, 2H, CH$_2$), 5.13 (s, 2H, OCH$_2$), 6.68 (bs, 1H, furyl), 6.95 (bs, 1H, furtyl), 7.68-7.86 (m, 4H, benzyl), 7.74 (bs, 1H, furyl), 8.06 (d, *J*=13.5Hz, 1H, H$_5$), 8.94 (s, 1H, H$_2$), 15.14 ppm (s, 1H, COOH); IR (KBr): 1720, 1634 (C=O). MS *m/z* 566 (M$^+$, 6), 319 (14), 234 (33), 141 (100).

7-(4-(2-(3-chlorobenzyloxyimino)-2-(furan-3-yl)ethyl)piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 7g

Yield: 49%; m.p. 229–230 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$):1.40 (t, *J*=6.3 Hz, 3H, CH$_3$), 2.56-2.64 (m, 4H, piperazine), 3.22-3.30 (m, 4H, piperazine), 3.63 (s, 2H, CH$_2$), 4.56 (q, *J*=6.3 Hz, 2H, CH$_2$), 5.18 (s, 2H, OCH$_2$), 6.68 (bs, 1H, furyl), 6.96 (bs, 1H, furyl), 7.15 (d, *J*=7.1Hz, 1H, H$_8$), 7.34-7.42 (m, 3H, benzyl), 7.74 (bs, 1H, furyl), 7.88 (s, *J*=13.2 Hz, 1H, H$_5$), 8.48 (s, 1H, benzyl), 8.93 (s, 1H, H$_2$), 15.30 ppm (s, 1H, COOH); IR (KBr): 1725, 1626 (C=O). MS *m/z* 566 (M$^+$, 6), 318 (29), 234 (16), 141 (100).

7-(4-(2-(3-chlorobenzyloxyimino)-2-(furan-3-yl)ethyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 7h

Yield: 65%; m.p. 269–270 ° C; ^{1}HNMR (500 MHz, DMSO-d$_6$): 1.16-1.19 (m, 2H, cyclopropyl), 1.29-13.33 (m, 2H, cylopropyl),

2.50-2.52 (m, 4H, piperazine), 2.98 (s, 2H, CH_2), 3.28-3.34 (m,4H, piperazine), 3.82-3.89 (m, 1H, cyclopropyl), 5.22 (s, 2H, OCH_2), 6.63-6.65 (m, 1H, furyl), 6.89-6.98 (m, 1H, furyl), 7.31-7.41 (m, 3H, benzyl), 7.55 (d, *J*=6.9 Hz, 1H, H_8), 7.76-7.83 (m,1H, furyl), 7.90 (d, *J*=13.1Hz, 1H, H_5), 8.67 (s, 1H, H_2), 15.13 ppm (s, 1H, COOH); IR (KBr): 1712, 1624 (C=O). MS *m/z* 578 (M^+, 2), 344 (34), 246 (7), 141 (100).

7-(4-(2-(3-chlorobenzyloxyimino)-2-(furan-3-yl)ethyl)piperazin-1-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 7i

Yield: 35%; m.p. 278–280 ° C; ^{1}HNMR (500 MHz, DMSO-d_6): 1.37 (t, *J*=6.9 Hz, 3H, CH_3), 2.48-2.59 (m, 4H, piperazine), 3.33 (s, 2H, CH_2), 3.74-3.80 (m, 4H, piperazine), 4.46 (q, *J*=6.9 Hz, 2H, CH_2), 5.22 (s, 2H, OCH_2), 6.95 (d, *J*=1.5Hz, 1H, furyl), 6.97(d, *J*=1.5 Hz, 1H, furyl), 7.31-7.45 (m, 3H, benzyl), 7.75 (t, *J*=1.5 Hz, 1H, furyl), 8.04 (d, *J*=13.5 Hz, 1H, H_5), 8.49 (s, 1H, benzyl), 8.95 (s, 1H, H_2), 15.30 ppm (s, 1H, COOH); IR (KBr): 1719, 1634 (C=O). MS *m/z* 567 (M^+, 3), 319 (19), 234 (41), 141 (100).

Cytotoxic evaluation

The synthesized compounds 7a-i were tested against different human breast tumor cell lines including MCF-7, MDA-MB-231 and T47D using MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reduction assay. The cell lines were purchased from National Cell Bank of Iran (NCBI). Cells were seeded in 96-well plates at the density of 10,000 viable cells per well and incubated at 37º C in a humidified atmosphere with 5% CO_2 for 24 h to allow cell attachment. The cells were then incubated for another 48 h with various concentrations of compounds 7a-i. The synthetic compounds were dissolved in DMSO and the final concentration of DMSO in each well was kept below 1%. etoposide was used as a positive control for each cell line. The medium was replaced with 200 µL RPMI-1640 without phenol red containing 0.5 mg/mL MTT. An additional 4h of incubation at 37 °C were done and then the medium was discarded. Dimethyl sulfoxide (100 µL) was added to each well and the solution was vigorously mixed to dissolve the purple tetrazolium crystals. The

absorbance of each well was measured by plate reader (Biotek Instruments, Winooski, Vt.) at a test wavelength of 492 nm. Three independent experiments in triplicate were performed for determination of sensitivity to each compound. The IC_{50} were calculated by linear regression analysis, expressed in mean ± SD.

Results and Discussion

Chemistry

The target compounds 7a-i were synthesized according to the procedure depicted in Scheme 1. Bromination of 1-(furan-2 or 3)-yl) ethanone in the presence of cupper II bromide in refluxing chloroform-ethyl acetate led to the formation of 1-(furan-2 or 3)-yl)ethanone 4a-b. Reaction of hydroxylamine hydrochloride and ethylchloroformate in sodium carbonate resulted in synthesis of ethyl hydroxy carbonate 1. Chlorobenzyl carbetoxy hydroxamate derivatives 2a-c were synthesized through the reaction of ethyl hydroxy carbonate 1 and different chlorobenzyl chloride derivatives in presence of sodium ethanolate at room temperature. Hydrolysis of resulted compounds 2a-c under basic condition led to production of *O*-chlorobenzylhydroxylamine hydrochloride 3a-c. Reaction of compounds 3a-c and 2-bromo-1-(furan-2 or 3)-yl) ethanone 4a-c in methanol resulted in synthesis of 2-bromo-1-(furan-2 or 3)-yl)ethanone *O*-chlorobenzyl oxime derivatives 5a-f. *N*-2-(2 or 3-furyl)-2-(chlorobenzyloxyimino) ethyl quinolone derivatives 7a-i were synthesized by reaction of different quinolone derivatives 6a-c and corresponding 2-bromo-1-(furan-2 or 3-yl) ethanone *O*-chlorobenzyloxime 5a-f in DMF in the presence of $NaHCO_3$ at ambient temperature (Scheme 1). Chemical structures of target compounds were characterized by IR, ^{1}HNMR and elemental analysis.

Cytotoxic activity

- The cytotoxic activity of target compounds 7a-i were assessed *in-vitro* against a panel of three human cancer cell lines including MCF-7, MDA-MB-231 and T47D. The percentage of cell growth was evaluated using MTT colorimetric assay in comparison with untreated controls. For each compound, the 50%

Scheme 1. Synthesis of *N*-2-(furyl)-2-(chlorobenzyloxyimino)ethyl quinolones (**6a-i**). Reagents and conditions: A) Na$_2$CO$_3$, H$_2$O, rt; B) Na, EtOH, rt; C) 1. NaOH, H$_2$O, heat, 2. EtOH, HCl; D) MeOH, rt; E) DMF, NaHCO$_3$, rt.

inhibitory concentration (IC$_{50}$) was determined and reported in Table 1. The corresponding data for etoposide was included for comparison. On the basis of obtained IC$_{50}$ values, most of synthesized compounds demonstrated potent to moderate cytotoxic potential especially against T47D cell line ((IC$_{50}$=2.20-39.08μM). However; most of evaluated derivatives were almost inactive against MDA-MB-231 cell line (IC$_{50}$>100 μM). The most promising compound

Table 1. Structures and *in-vitro* cytotoxicity of compounds 7a-i against three different human breast cancer cell lines assessed by MTT reduction assay[a].

Compound	X	Ar	Y	R	MCF-7 IC$_{50}$ (µg/ml)	MDA-MB-231 IC$_{50}$ (µg/ml)	T47D IC$_{50}$ (µg/ml)
7a	CH		H	Et	5.30±4.7	>100[b]	7.00±5.09
7b	CH		4-Cl	Et	12.35±1.7	>100	8.70±2.5
7c	CH		2-Cl	Et	7.50±1.1	>100	7.60±2.1
7d	N		2-Cl	Et	>100	>100	10.05±1.6
7e	CH		4-Cl	Et	11.40±2.7	65.4±5.4	10.90±1.9
7f	N		4-Cl	Et	10.05±1.9	77.00±6.3	15.20±1.1
7g	CH		3-Cl	Et	3.03±1.5	11.90±2.6	2.20±1.5
7h	CH		3-Cl		>100	>100	12.35±1.6
7i	N		3-Cl	Et	>100	>100	39.08±8.4
Etoposide	---	---	---	---	7.9±	11.1±	8±

[a] Values represent the mean± SD of three different experiments.

[b] Compounds were tested at the maximum final concentration of 100 µg/mL.

of this series 7g, ethyl quinolone derivative (X=CH and R=Et) containing 3-furyl moiety (Ar=3-furyl) and 3-chloro phenyl (Y=3-Cl), demonstrated significant growth inhibitory potential against all evaluated cell lines (the corresponding IC$_{50}$ values against MCF-7, MDA-MB-231 and T47D cells were 3.03, 11.90 and 2.20 µM, respectively). Moreover, 7 g demonstrated superior cytotoxic activity compared to reference compound, etoposide (the corresponding IC$_{50}$ values against MCF-7, MDA-MB-231 and T47D cells were 7.9±Quinolone derivatives were more potent cytotoxic agents than 1, 8-naphthyridones in most cases; e.g ethyl quinolone compound 7 g (Ar=3-furyl, Y=3-Cl) was found to be most potent cytotoxic derivative. However, its 1-ethyl 1,8-naphthyridinone counterpart 7i was almost inactive against MCF-7 and MDA-MB-231 (IC$_{50}$>100µM) and showed weak growth inhibitory potential toward T47D cells (IC$_{50}$=39.08µM).

- Ethyl quinolones demonstrated high cytotoxic potential over cyclopropyl quinolones; *e.g.* compound 7 g was potent cytotoxic agent

of these series (the corresponding IC_{50} values against MCF-7, MDA-MB-231 and T47D cells were 3.03, 11.90 and 2.20 µM, respectively). While its cyclopropyl quinolone counterpart 7h was inactive against MCF-7 and MDA-MB-231 cancer cells (IC_{50}>100 µM) and showed moderate cytotoxic potential against T47D cells (IC_{50}=12.35µM).

- Considering the substituted moiety on the oxime pendant (Ar group), no significant differences were observed between cytotoxic potentials of 2-furyl and 3-furyl derivatives; *i.e.* compound 7e, ethyl quinolone derivative containing 3-furyl substitute on the oxime pendant (Y=4-Cl) and its 2-furyl counterpart 7b, demonstrated potent cytotoxic potential against MCF-7 (7b (IC_{50}=12.35 µM) and 7e (IC_{50}=11.40 µM)) and T47D cells (7b (IC_{50}=8.70µM) and 7e (IC_{50}=10.90µM)). Both compounds were almost inactive against MDA-MB-231 cells.

Conclusion

In conclusion, a novel series of 6-fluoro quinolone 3-carboxylic acid and 6-fluroro-1,8-naphthyridone 3-carboxylic acid derivatives containing *N*-2-(2-furyl)-2-(chlorobenzyloxyimino)ethyl or *N*-2-(3-furyl)-2-(chlorobenzyloxyimino)ethyl piperazinyl pendant attached to the central core was synthesized and evaluated against three different human cancer cell lines. The most promising compound of ethyl quinolone series, 7 g, demonstrated significant growth inhibitory potential against all evaluated cell lines. The results of structure-activity relationship study demonstrated that quinolone derivatives are superior in cytotoxic potential compared to 1,8-naphthyridone series. Furthermore, ethyl quinolone derivatives were more potent cytotoxic agents than cyclopropyl quinolones.

Acknowledgment

References

(1) De Sarro A and De Sarro G. Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. *Curr. Med. Chem.* (2001) 8: 371-84.

(2) Efthimiadou EK, Thomadaki H, Sanakis Y, Raptopoulou CP, Katsaros N, Scorilas A, Karaliota A and Psomas G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2›-bipyridine. *J. Inorg. Biochem.* (2007) 101: 64-73.

(3) Ghorab MM, Ragab FA, Heiba HI, Nissan YM and Ghorab WM. Novel brominated quinoline and pyrimidoquinoline derivatives as potential cytotoxic agents with synergistic effects of gamma-radiation. *Arch. Pharmcal. Res.* (2012) 35: 1335-1346.

(4) Tuma J, Connors WH, Stitelman DH and Richert C. On the effect of covalently appended quinolones on termini of DNA duplexes. *J. Am. Chem. Soc.* (2002) 124: 4236-4246.

(5) Drlica K. Mechanism of fluoroquinolone action. *Curr. Opin. Microbiol.* (1999) 2: 504-508.

(6) Chen AY and Liu LF. DNA topoisomerases: essential enzymes and lethal targets. *Annu. Rev. Pharmacol. Toxicol.* (1994) 34: 191-218.

(7) Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA and Silverman JA. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine *in-vitro* and induces bone marrow aplasia *in-vivo*. *Cancer. Chemoth. Pharm.* (2010) 66: 881-888.

(8) Lai YY, Huang LJ, Lee KH, Xiao Z, Bastow KF, Yamori T and Kuo SC. Synthesis and biological relationships of 3›,6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. *Bioorg. Med. Chem.* (2005) 13: 265-275.

(9) Xia Y, Yang ZY, Morris-Natschke SL and Lee KH. Recent advances in the discovery and development of quinolones and analogs as antitumor agents. *Curr. Med. Chem.* (1999) 6: 179-194.

(10) Miri R, Firuzi O, Peymani P, Nazarian Z and Shafiee A. Synthesis and cytotoxicity study of new cyclopenta [b] quinoline-1,8-dione derivatives. *Iran. J. Pharm. Res.* (2011) 10: 489-496.

(11) Chen YC, Lu PH, Pan SL, Teng CM, Kuo SC, Lin TP, Ho YF, Huang YC and Guh JH. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. *Biochem. Pharmacol.* (2007) 74: 10-19.

(12) Hsu SC, Yang JS, Kuo CL, Lo C, Lin JP, Hsia TC, Lin JJ, Lai KC, Kuo HM and Huang LJ. Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. *J. Orthopaed. Res.* (2009) 27: 1637-1644.

(13) Chang YH, Yang JS, Kuo SC and Chung JG. Induction of mitotic arrest and apoptosis by a novel synthetic quinolone analogue, CWC-8, via intrinsic and extrinsic apoptotic pathways in human osteogenic sarcoma U-2 OS cells. *Anticancer. Res.* (2009) 29: 3139-3148.

(14) Rajabalian S, Foroumadi A, Shafiee A and Emami S. Functionalized N(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents. *J. Pharm. Pharm. Sci.* (2007) 10: 153-158.

(15) Elsea SH, Mcguirk PR, Gootz TD, Moynihan M and Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage *in-vitro* and cytotoxic potential. *Antimicrob. Agents Chemother.* (1993) 37: 2179-2186.

(16) Kohlbrenner WE, Wideburg N, Weigl D, Saldivar A and Chu DT. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. *Antimicrob. Agents Chemother.* (1992) 36: 81-86.

(17) Foroumadi A, Emami S, Rajabalian S, Badinloo M, Mohammadhosseini N and Shafiee A. N-Substituted piperazinyl quinolones as potential cytotoxic agents: structure-activity relationships study. *Biomed. Pharmacother.* (2009) 63: 216-220.

(18) Alipour E, Hosseini NM, Panah F, Ardestani SK, Safavi M, Shafiee A and Foroumadi A. Synthesis and *in-vitro* cytotoxic activity of n-2-(2-furyl)-2-(chlorobenzyloxyimino) ethyl ciprofloxacin derivatives. *J. Chem.* (2011) 8: 1226-1231.

(19) Foroumadi A, Mohammadhosseini N, Emami S, Letafat B, Faramarzi MA, Samadi N and Shafiee A. Synthesis and antibacterial activity of new 7-piperazinyl-quinolones containing a functionalized 2-(furan-3-yl)ethyl moiety. *Arch. Pharm.* (2007) 340: 47-52.

(20) Zonouzi A, Mirzazadeh R, Safavi M, Kabudanian Ardestani S, Emami S and Foroumadi A. 2-Amino-4-(nitroalkyl)-4H-chromene-3-carbonitriles as New Cytotoxic Agents. *Iran. J. Pharm. Res.* (2013) 12: 679-685.

(21) Vosooghi M, Yahyavi H, Divsalar K, Shamsa H, Kheirollahi A, Safavi M, Ardestani SK, Sadeghi-Neshat S, Mohammadhosseini N, Edraki N, Khoshneviszadeh M, Shafiee A and Foroumadi A. Synthesis and *In-vitro* cytotoxic activity evaluation of (E)-16-(substituted benzylidene) derivatives of dehydroepiandrosterone. *Daru* (2013) 21: 34.

(22) Hajmohamad Ebrahim Ketabforoosh S, Amini M, Vosooghi M, Shafiee A, Azizi E and Kobarfard F. Synthesis, evaluation of anticancer activity and QSAR study of heterocyclic esters of caffeic Acid. *Iran. J. Pharm. Res.* (2013) 12: 705-719.

(23) Noushini S, Alipour E, Emami S, Safavi M, Ardestani SK, Gohari AR, Shafiee A and Foroumadi A. Synthesis and cytotoxic properties of novel (E)-3-benzylidene-7-methoxychroman-4-one derivatives. *Daru* (2013) 2: 31.

This article is available online at http://www.ijpr.ir

Search full text articles?
Visit http://www.ijpr.ir
or
http:// ijpr.sbmu.ac.ir